Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × dalotuzumab × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5 Breast 3 Tumor-Agnostic 1 Plasma cell 1 Other solid neoplasm 1 NET 1 Gynecologic 1 Endocrine 1

Conditions

Advanced Solid Tumors 1

Interventions

Cisplatin 24 Pemetrexed 23 Nivolumab 18 pembrolizumab 17 Carboplatin 16 Paclitaxel 12 Gemcitabine 12 Ipilimumab 11 Docetaxel 8 tislelizumab 7 talazoparib 7 durvalumab 6 Ramucirumab 6 Radiotherapy 6 Fluorouracil 6 Capecitabine 6 cobimetinib 5 atezolizumab 5 Radiosurgery 5 Cyclophosphamide 5 tremelimumab 4 olaparib 4 adavosertib 4 Temozolomide 4 Sunitinib 4 Specimen Handling 4 Platinum 4 PM 01183 4 Itraconazole 4 Biopsy 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00635778 2018-10-09

MK-0646-002

Merck Sharp & Dohme LLC

Phase 1 Completed

50 enrolled 32 charts

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡